Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis

An analysis is presented to compare the efficacies of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) and tamsulosin in patients with benign prostatic hyperplasia (BPH), collecting data from a published 20-week, randomized, double-blind, crossover study. Results demonstrated that after 8 weeks of treatment, both doxazosin-GITS and tamsulosin provided significant (p < 0.001) improvement from baseline in total international prostate symptom score (IPSS) and obstructive and irritative subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.019 between-group difference for total IPSS; p = 0.001 for irritative subscore). Similarly, after the first 4 weeks of treatment, prior to dose titration, both doxazosin-GITS and tamsulosin provided significant (p ≤ 0.001) improvement in total IPSS and subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.045 between-group difference for obstructive subscore). These data confirm that the efficacy of doxazosin is superior to that of tamsulosin in the management of patients with BPH.